The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
Allogeneic natural killer T cells (NKTs) expressing CD19-specific chimeric antigen receptors (CARs) are well tolerated and can mediate objective responses in non-Hodgkin’s lymphoma
Dr. Mateos was the lead investigator on the trial, which investigated belantamab mafodotin (blenrep) with bortezomib and dexamethasone (BVd) versus daratumumab with bortezomib
Novel product candidate M2T-CD33 (LTI-214) was granted orphan drug designation by the US Food and Drug Administration for the treatment of acute myeloid
In this interview at the Thirteenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2025), Elias Jabbour, MD, leukemia professor at the
Patients with chronic lymphocytic leukemia (CLL) who have a body mass index (BMI) of 40 or higher (obesity class 3) are at a
In this episode of the SOHO Insider podcast, Susan O’Brien, MD, a professor of medicine from the Chao Family Comprehensive Cancer Center at
The US Food and Drug Administration (FDA) has approved revumenib (Revuforj®) in patients with relapsed or refractory NPM1-mutated acute myeloid leukemia (AML). The
Clinical cancer research remains too expensive and too burdensome, even amid a proliferation of digital tools designed to improve it, according to Ines
Updated results from a phase 1/2 trial of bexmarilimab plus azacitidine continue to support the efficacy of the combination in treatment-naïve patients with
The study, presented by Guillermo Garcia-Manero, MD, interim chair of the Department of Leukemia at the University of Texas MD Anderson Cancer Center,
